Jakavi 10mg Tablet

• Treat blood disorders, including myelofibrosis and polycythemia vera

Every medication has several side effects that are harmful to the body if not treated early. If you experience any of the symptoms, visit the doctor immediately to avoid complications during the treatment. Common ones include:

• Low red and white blood cell counts
• Low platelet counts
• Dizziness, headache
• Bruising
• Diarrhea
• Infections, including viral infections
• Swelling in the face and body
• Fatigue or tiredness

• Severe infections like hepatitis B
• Anemia
• Bleeding

Jakavi 10mg tablet should be taken with or without food at the fixed time everyday as recommended by the healthcare professional. Do not crush, break, or chew the tablet just swallow it whole glass of water. The doctor will decide the correct dosage and duration based on the patient's height, weight and response to the treatment. Always take the tablet according to the healthcare professional.

Jakavi 10mg tablet works by inhibiting the JAK1 and JAK2 enzyme, which are involved in signaling pathways that regulate blood cell production and immune activity. By blocking the enzymes it helps reduce abnormal cell growth, lower inflammation and shrink enlarged spleens. Thereby improving disease related symptoms and overall quality of life in affected patients.

• Mascarenhas, J., & Hoffman, R. (2012). Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clinical cancer research, 18(11), 3008-3014. https://pubmed.ncbi.nlm.nih.gov/22474318/
• Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., ... & Kantarjian, H. M. (2012). A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. New England Journal of Medicine, 366(9), 799-807. https://pubmed.ncbi.nlm.nih.gov/22375971/
• Elli, E. M., Baratè, C., Mendicino, F., Palandri, F., & Palumbo, G. A. (2019). Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib. Frontiers in oncology, 9, 1186.
• Vannucchi, A. M., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., ... & Verstovsek, S. (2015). Ruxolitinib versus standard therapy for the treatment of polycythemia vera. New England Journal of Medicine, 372(5), 426-435.
• Harrison, C., Kiladjian, J. J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., ... & Barosi, G. (2012). JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine, 366(9), 787-798